Atara Biotherapeutics logo

Atara BiotherapeuticsNASDAQ: ATRA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 October 2014

Next earnings report:

28 March 2025

Last dividends:

N/A

Next dividends:

N/A
$67.10 M
-95%vs. 3y high
39%vs. sector
-vs. 3y high
-vs. sector
-102%vs. 3y high
12%vs. sector
-99%vs. 3y high
17%vs. sector

Price

after hours | Wed, 20 Nov 2024 00:54:29 GMT
$11.65$0.00(0.00%)

Dividend

No data over the past 3 years
$40.19 M$27.33 M
$40.19 M-$21.91 M

Analysts recommendations

Institutional Ownership

ATRA Latest News

Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
zacks.com12 November 2024 Sentiment: POSITIVE

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $2.93 per share versus the Zacks Consensus Estimate of a loss of $3.77. This compares to loss of $16.50 per share a year ago.

Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know
zacks.com15 October 2024 Sentiment: POSITIVE

Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates
zacks.com12 August 2024 Sentiment: NEGATIVE

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $3.10 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to loss of $17 per share a year ago.

Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
businesswire.com12 August 2024 Sentiment: POSITIVE

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2024, recent business highlights, and key upcoming milestones for 2024. “Building on the recent BLA acceptance with Priority Review for tab-cel, we are making signifi.

All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy
zacks.com15 July 2024 Sentiment: POSITIVE

Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
businesswire.com03 July 2024 Sentiment: POSITIVE

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Virtual Cell Therapy Forum on Tuesday, July 9, 2024 at 6:45 a.m. PDT / 9:45 a.m. EDT. A live web.

Atara Biotherapeutics' Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
businesswire.com21 June 2024 Sentiment: POSITIVE

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that EbvalloTM (tabelecleucel or tab-cel®) has been awarded the prestigious 2024 Prix Galien International Award for “Best Product for Orphan/Rare Diseases.” The award was presented to Pierre Fabre Laborato.

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
businesswire.com20 May 2024 Sentiment: POSITIVE

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Atara has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (tab-cel®) indicated as monotherapy for treatment of adult and pediatric patie.

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research28 March 2024 Sentiment: POSITIVE

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.72 per share a year ago.

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway
Seeking Alpha05 February 2024 Sentiment: POSITIVE

Atara Biotherapeutics is a biotech company focused on developing cell therapies for Epstein-Barr virus infection and cancer. Their most advanced product, tab-cel, has shown promising results in treating EBV-associated post-transplant lymphoproliferative disease. The company's financial situation is uncertain, but recent partnerships and potential revenue growth from tab-cel could improve their cash runway.

What type of business is Atara Biotherapeutics?

Atara Biotherapeutics, Inc. is a biotechnology company that is developing new methods of treating patients with cancer, autoimmune, and viral diseases. The company specializes in allogeneic T-cell immunotherapy. It was founded in 2012 and is headquartered in San Francisco, California. The company's priority programs/strategies are: - Tab-cel: an advanced T-cell immunotherapy in Phase 3 clinical development, designed for patients with Epstein-Barr virus. - ATA188: T-cell immunotherapy targeting EBV antigens, considered important for potential treatment of multiple sclerosis. - ATA2271/ATA3271: immunotherapy for patients with hematologic malignancies, solid tumors, and viral diseases. - ATA3219: immunotherapy aimed at treating patients with B-cell lymphomas.

What sector is Atara Biotherapeutics in?

Atara Biotherapeutics is in the Healthcare sector

What industry is Atara Biotherapeutics in?

Atara Biotherapeutics is in the Biotechnology industry

What country is Atara Biotherapeutics from?

Atara Biotherapeutics is headquartered in United States

When did Atara Biotherapeutics go public?

Atara Biotherapeutics initial public offering (IPO) was on 16 October 2014

What is Atara Biotherapeutics website?

https://www.atarabio.com

Is Atara Biotherapeutics in the S&P 500?

No, Atara Biotherapeutics is not included in the S&P 500 index

Is Atara Biotherapeutics in the NASDAQ 100?

No, Atara Biotherapeutics is not included in the NASDAQ 100 index

Is Atara Biotherapeutics in the Dow Jones?

No, Atara Biotherapeutics is not included in the Dow Jones index

When was Atara Biotherapeutics the previous earnings report?

No data

When does Atara Biotherapeutics earnings report?

The next expected earnings date for Atara Biotherapeutics is 28 March 2025